About this item:

738 Views | 420 Downloads

Author Notes:

Correspondence to: Guillermo E. Umpierrez, Division of Endocrinology, Emory University School of Medicine, 49 Jesse Hill Jr Dr, Atlanta, Georgia, 30303, USA. E‐mail: geumpie@emory.edu.

G. U. contributed to design, conduct/data collection, and analysis of the paper.

K. P. contributed to analysis of the paper.

A. K. contributed to design and analysis of the paper.

A. Z. contributed to analysis of the paper.

N. Z. contributed to design, analysis, and writing of the paper.

L. F. contributed to design and analysis of the paper.

Please see the full article for Conflicts of Interest.

Subjects:

Research Funding:

This work was sponsored by Eli Lilly and Company.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Endocrinology & Metabolism
  • dulaglutide
  • GLP-1 analogueincretin therapy
  • incretin therapy
  • type 2 diabetes
  • CARDIOVASCULAR RISK
  • CENTERED APPROACH
  • NON-INFERIORITY
  • OPEN-LABEL
  • MANAGEMENT
  • EFFICACY
  • SAFETY
  • TRIAL
  • LIRAGLUTIDE
  • ASSOCIATION

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment

Tools:

Journal Title:

Diabetes, Obesity and Metabolism

Volume:

Volume 18, Number 6

Publisher:

, Pages 615-622

Type of Work:

Article | Final Publisher PDF

Abstract:

Aim: To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide‐treated patients by analysing data from six head‐to‐head phase III AWARD clinical trials. Methods: At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy. The effect of baseline characteristics was also evaluated with regard to weight and HbA1c response. Results: Across the studies, 87–97% and 83–95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57–88% and 43–84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss. The majority (55–83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41–79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level. A weak and inconsistent correlation was observed between the changes in weight and HbA1c (range from −0.223 to 0.267) in patients treated with dulaglutide. The baseline characteristics of gender, age, duration of diabetes, HbA1c, body weight and BMI were not related to different combinations of weight and HbA1c responses. Conclusions: Dulaglutide is an effective treatment option across the type 2 diabetes treatment spectrum. Dulaglutide showed dose‐dependent effects on both weight loss and HbA1c reduction. These effects had a weak correlation and appeared to be independent.

Copyright information:

© 2016 The Authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote